COINS Seminar #51【Date】17/December/2019（Tue.）16:00 – 17:30 (Registration Open at 15:30)＊Research Mixer 17:30-18:15 *JPY500【Venue】Innovation Center of NanoMedicine (iCONM) 3F 3001 Meeting room
【Registration】URL: https://www.cis-trans.jp/coins_seminar51/index.html◆Part 1 16:00-16:45
Title:Nano on ICU: Overcoming limitations for the treatment of organ failure
Hepatic dysfunction and jaundice are late features of sepsis associated with poor outcomes.
Phosphoinositide 3-kinases (PI3K) mediate critical functions in multiple cells, affecting amongothers, hepatocellular phase I, II, and III metabolism, immune cell recruitment and hostdefense. We and others have shown that mice lacking PI3K-γ are protected against hepaticexcretory dysfunction while exhibiting a severe immune defect that disturbs recruitment of
neutrophils to sites of infection. Thus, in order to exploit the therapeutic potential of (amongothers) PI3K-γ inhibitors, targeted delivery strategies enabling compartmentalized inhibitionof kinase function in selected tissues or organs while maintaining critical immune functions arecritical for the development of novel therapeutics.
Speaker:Prof. Dr. Michael Bauer
Affiliation:Jena University Hospital, Dep. Anesthesiology& Intensive Care Medicine
Position:Director
URL:https://www.uniklinikum-jena.de/kai/… since April 20162010-2016

Director, Dept. of Anaesthesiology and Intensive Care Medicine,
Jena University Hospital
Professor (W3) and Chief-Executive-Director, Center for Sepsis
Control and Care, Jena University Hospital

2004-2010

Professor (C3) and vice chair, Dept. of Anaesthesiology andIntensive Care Medicine, Jena University Hospital

1998-1999

Visiting adjunct professor, Dept. of Biology, University of North
Carolina, Charlotte, USASelected publications:
1. Bauer M et al. Remembering Pathogen Dose: Long-Term Adaptation in InnateImmunity. Trends Immunol. 2018 Jun;39(6):438-445..
2. Weis S, Carlos AR, Moita MR, Singh S, Blankenhaus B, Cardoso S, Larsen R,Rebelo S, Schäuble S, Del Barrio L, Mithieux G, Rajas F, Lindig S, Bauer M, Soares
MP. Metabolic Adaptation Establishes Disease Tolerance to Sepsis. Cell. 2017
3. Seidel RA, Claudel T, Schleser F, Ojha NK, Westerhausen M, Nietzsche S, Karailieva
D, Sponholz C, Cuperus F, Coldewey SM, Heinemann SH, Pohnert G, Trauner M,Bauer M. Impact of higher-order heme degradation products on hepatic
hemodynamics, function and integrity. J Hepatol 2017
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M,
Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM,Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus
DC (2016). The 3rd International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 315: 801-10.
5. Press AT, Ramoji A., von der Lühe M, Rinkenauer AC, Hoff J, Butans M, Rössel C,Pietsch C, Neugebauer U, Schacher FH, Bauer M. Cargo-carrier interactions
significantly contribute to micellar conformation and biodistribution. NPG Asia
Materials volume 9, pagee444 (2017)◆Part 2 16:45-17:30
Title:Raman spectroscopic imaging reveals changes in the micellar conformation dictating
pharmacokinetic properties
Strategies to deliver drugs using nanocarriers, which are passively or actively targeted to their
alleged site of action, might affect benefit-risk-profiles of novel therapeutics favorably. Werecently demonstrated interactions within or in-between carrier and cargo are influencing thepharmacokinetic properties such as biodistribution, hence must be considered while designingtranslational nanocarrier platforms. To understand the surface changes affecting the biomedical
applications in sub-100 nm micelles suitable methods are missing.
Speaker:Dr. Adrian T. Press
Affiliation:Jena University Hospital, Nanophysiology Group
Position:Group leader
https://www.uniklinikumjena.de/kai/Forschung+_+Research/Nanophysiologie.html… since 20162016

Group leader, Nanophysiology Group, Jena University Hospital
PhD in Molecular Biomedicine ((Friedrich-Schiller University, Jena,Germany)

2015

Master of Science in Molecular Medicine (Friedrich-SchillerUniversity, Jena, Germany)

2013

Bachelor of Science in Molecular and Technical Medicine(Furtwangen University, Germany)

Selected publications:
Press AT, Traeger A, Pietsch C, Mosig A, Wagner M, Clemens MG, Jbeily N, Koch N,
Gottschaldt M, Bézière N, Ermolayev V, Ntziachristos V, Popp J, Kessels MM, Qualmann B,Schubert US, Bauer M, Cell type-specific delivery of short interfering RNAs by dyefunctionalised theranostic nanoparticles. Nat Commun. 2014; 3(5):5565
Rinkenauer AC, Press AT, Raasch M, Pietsch C, Schweizer S, Schwörer S, Rudolph KL,Mosig A, Bauer M, Traeger A, Schubert US, Comparison of the uptake of methacrylatebased nanoparticles in static and dynamic in vitro systems as well as in vivo. J Control
Release. 2015; 28(216):158-68
Press AT, Ramoji A, Moritz vd. Lühe, Alexandra C. Rinkenauer, Jessica Hoff, Marianne
Butans, Rössel C, Pietsch C, Neugebauer U, Schacher FH, Bauer M, Cargo–carrierinteractions significantly contribute to micellar conformation and biodistribution.NPG
Asia Materials 2017; 9:e444
Schaarschmidt B, Vlaic S, Medyukhina A, Neugebauer S, Nietzsche S, Gonnert FA, Rödel J ,Singer M, Kiehntopf M, Figge MT, Jacobsen ID, Bauer M, Adrian AT, Molecularsignatures of liver dysfunction are distinct in fungal and bacterial infections in
mice.Theranostics 2018; 8(14):3766-3780*Supported by: COINS（JST, COIProgram）, Innovation Center of NanoMedicine（iCONM）